NCT01500200 - A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) | Biotech Hunter

Enrollment

142

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Major Depressive Disorder

Interventions

DRUG

ALKS 5461

Two active tablets, given daily

DRUG

Placebo

Two placebo tablets, given daily

Trial Locations (27)

10021

Alkermes Investigational Site, New York

11241

Alkermes Investigational Site, Brooklyn

19104

Alkermes Investigational Site, Philadelphia

21285

Alkermes Investigational Site, Baltimore

29407

Alkermes Investigational Site, Charleston

30308

Alkermes Investigational Site, Atlanta

33161

Alkermes Investigational Site, North Miami

33319

Alkermes Investigational Site, Lauderhill

33716

Alkermes Investigational Site, St. Petersburg

33912

Alkermes Investigational Site, Fort Myers

34748

Alkermes Investigational Site, Leesburg

44718

Alkermes Investigational Site, Canton

45417

Alkermes Investigational Site, Dayton

60169

Alkermes Investigational Site, Hoffman Estates

73112

Alkermes Investigational Site, Oklahoma City

75235

Alkermes Investigational Site, Dallas

77081

Alkermes Investigational Site, Houston

78229

Alkermes Investigational Site, San Antonio

78754

Alkermes Investigational Site, Austin

85712

Alkermes Investigational Site, Tucson

90502

Alkermes Investigational Site, Torrance

92056

Alkermes Investigational Site, Oceanside

92701

Alkermes Investigational Site, Santa Ana

98007

Alkermes Investigational Site, Bellevue

02135

Alkermes Investigational Site, Boston

01830

Alkermes Investigational Site, Haverhill

08009

Alkermes Investigational Site, Berlin